Fractyl Health, Inc 8-K/A, filed Nov 19, 2026
Fractyl Health, Inc. (GUTS)
About this 8-K/A
Fractyl Health, Inc filed this 8-K/A on November 19, 2026, reporting on events of October 21, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Explanatory Note
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Retirement of Executive Officer
As previously disclosed on October 22, 2026, effective as of October 30, 2026, Jay Caplan retired from the Company as its President and Chief Product Officer.
In connection with Mr. Caplan’s retirement, on November 16, 2026, Mr. Caplan and the Company entered into the Separation Agreement. Subject to the Separation Agreement becoming effective following expiration of the applicable revocation period and Mr. Caplan’s continued compliance with his restrictive covenant obligations, Mr. Caplan will receive (i) cash payments of $515,000, equal to 12 months of his annual base salary, payable in accordance with the Company’s normal payroll schedule and (ii) up to 12 months of Company-paid COBRA continuation coverage. The Separation Agreement includes a release of claims.
In addition, on November 19, 2026, Mr. Caplan and the Company entered into the Consulting Agreement, effective as of October 31, 2026, pursuant to which Mr. Caplan will provide consulting services to the Company during this transition for an initial term of six months from the effective date, pursuant to which the Company will pay Mr. Caplan an hourly rate of $250.00 for the time spent performing such services, subject to a cap of 40 hours per month and any withholding required by applicable law. The Consulting Agreement does not guarantee any minimum level of services and may be terminated for convenience by the Company on 30 days’ prior written notice or by Mr. Caplan on 60 days’ prior written notice.
Copies of the Separation Agreement and Consulting Agreement are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively. The above descriptions of the material terms of the Separation Agreement and Consulting Agreement do not purport to be complete and are qualified in their entirety by reference to the applicable Exhibit.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
10.1 |
|
|
10.2 |
|
Consulting Agreement by and between Fractyl Health, Inc. and Jay Caplan effective October 31, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Fractyl Health, Inc. |
|
|
|
|
Date: |
November 19, 2026 |
By: |
/s/ Harith Rajagopalan |
|
|
|
Harith Rajagopalan, M.D., Ph.D. |
Exhibit 10.1
Separation Agreement and Release
This Separation Agreement and Release (“Agreement”) is made by and between Jay Caplan (“Executive”) and Fractyl Health, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below).
WHEREAS, the Parties have previously entered into that certain Employment Agreement, dated as of January 26, 2024 (the “Employment Agreement”) and the restrictive covenants in that certain employment letter agreement, dated as of June 21, 2011 (the “Restrictive Covenant Agreement”); and
WHEREAS, in connection with Executive’s termination of employment with the Company or a subsidiary or affiliate of the Company effective October 30, 2026 (the “Separation Date”), the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to Executive’s employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt, nothing herein will be deemed to release any rights or remedies in connection with Executive’s ownership of vested equity securities of the Company, vested benefits or Executive’s right to indemnification by the Company or any of its affiliates pursuant to contract or applicable law (collectively, the “Retained Claims”).
NOW, THEREFORE, in consideration of the severance payments and benefits described in Section 4 of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive’s execution and non-revocation of this Agreement, and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows:
Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not release claims that cannot be released as a matter of law, including, but not limited to, Executive’s right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company (with the understanding that Executive’s release of claims herein bars Executive from recovering such monetary relief from Parent, the Company or any other Releasee), claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA, claims to any benefit entitlements vested as the date of separation of Executive’s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive’s right under applicable law, and any Retained Claims. This release
further does not prevent Executive from (i) reporting possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of any whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies), (ii) exercising any rights Executive may have under Section 7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity, including collective action or discussion concerning wages or working conditions, or (iii) discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any other conduct that Executive has reason to believe is unlawful. This release further does not release claims for breach of Section 3(c) or Section 4 of the Employment Agreement.
IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below.
|
EXECUTIVE |
Dated: November 16, 2026 |
/s/Jay Caplan Jay Caplan |
|
FRACTYL HEALTH, INC. |
Dated: November 16, 2026 |
By: /s/Harith Rajagopalan Name: Harith Rajagopalan Title: Co-Founder, President, Chief Executive Officer |
EXHIBIT A
Restrictive Covenant Agreement
[attached]
Exhibit 10.2
CONSULTING AGREEMENT
THIS CONSULTING AGREEMENT (the “Agreement”), dated as of October 31, 2026 (the “Effective Date”), is made between Fractyl Health, Inc., a Delaware corporation with a principal place of business at 3 Van de Graaff Drive, Suite 200, Burlington, MA 01803 (the “Company”), and Jay Caplan (“Consultant”), each, a “Party” and collectively, the “Parties”.
Whereas, the Company desires to have the benefit of Consultant’s knowledge and experience in the development of the Company’s technology base and in the general development of the Company’s business, and Consultant desires to provide consulting services to the Company, all as hereinafter provided in this Agreement;
NOW THEREFORE, in consideration of the promises and mutual agreements hereinafter set forth, effective as of the Effective Date, the Company and Consultant hereby agree as follows:
Fractyl Health Consulting Agreement with Jay Caplan
Page 1 of 12
Fractyl Health Consulting Agreement with Jay Caplan
Page 2 of 12
Fractyl Health Consulting Agreement with Jay Caplan
Page 3 of 12
Fractyl Health Consulting Agreement with Jay Caplan
Page 4 of 12
9.1. General Compliance with Laws. Consultant represents, warrants and covenants that it is in compliance with and shall comply with all applicable laws, regulations, codes and ordinances, including without limitation all the licenses, permissions, authorizations, consents, and permits that it needs to carry out its obligations under this Agreement, including, as applicable and without limitation, the U.S. Foreign Corrupt Practices Act of 1977 (FCPA), the U.S. Anti-Kickback Statute, the U.K. Bribery Act of 2010, General Data Protection Regulation (GDPR) and any other applicable anti-corruption, anti-bribery, and anti-kickback laws.
9.2. Compliance with Anti-Bribery Laws. Without limiting Consultant’s obligations under Section 9, the Parties agree and understand that they will comply with all applicable anti-bribery laws, including the United States Foreign Corrupt Practices Act (“FCPA”), the U.K. Bribery Act and all other applicable laws and represent that no payments of money or anything of value will be offered, promised or paid, directly or indirectly, to any foreign government official, foreign political party or party official, or any candidate for foreign political office, to influence the acts of the government official, political party or candidate to induce the government official, political party or candidate to use Consultant’s influence with a government or instrumentality thereof, or to obtain an improper advantage in connection with any business venture, contract or agreement in which Company is a participant.
For purposes of this Agreement, a “Government Official” includes any appointed, elected, or honorary official or any career employee of the government of any national, regional or local
Fractyl Health Consulting Agreement with Jay Caplan
Page 5 of 12
government, or of a public international organization, or any political party, party official or candidate in any country. The “government” includes any agency, department, embassy or other government entity or public international organization. It also includes any company or other entity owned or controlled by the government. A person does not cease to be a Government Official by purporting to act in a private capacity or by the fact that the person serves without compensation.
Consultant shall not, directly or indirectly, offer, give, solicit, or accept any bribe, kickback, or other improper payment or benefit to or from any person or entity, including government officials, healthcare professionals, or customers, in connection with the performance of this Agreement.
9.3. Restriction on Government and Political Activities. The Consultant represents and warrants the following, except for disclosures made to the Company in writing as of the date of this Agreement:
9.3.1. Consultant is not a Government Official, political party official or candidate for political office;
9.3.2. None of its officers, directors, employees, or principal owners is a member of the immediate family (spouse, parent, child, sibling or sibling’s spouse) of, or financially dependent on, a Government Official, political party official or candidate for political office;
9.3.3. None of its officers, directors or employees is a Government Official, political party official or candidate for political office;
9.3.4. No Government Official, political party official, or candidate for political office, is directly or indirectly a principal owner or investor in the Consultant and no Government Official, political party official, or candidate for political office has any substantial financial interest in the contractual relationship established by this Agreement;
9.3.5. The Consultant agrees that Consultant will not communicate or meet with a Government Official, political party official, or candidate for political office in connection with this Agreement without prior Company approval;
9.3.6. The Consultant warrants that neither Consultant nor any party on its behalf will pay, offer, agree to pay, or cause to be paid, directly or indirectly, any loan, gift, donation, payment or other contribution to or for the benefit of, or at the direction of, any elected public official, any candidate or campaign for public office, any official of a political party or any employee of a political party, where such payment, offer or agreement is in any way connected to Company or the Services, without prior Company approval.
9.4. Books and Records; Compliance Cooperation. Consultant shall maintain accurate books and records and shall implement adequate internal controls to ensure compliance with such laws. Upon request, Consultant shall certify its compliance with this Section and cooperate in any audit or investigation related to anti-corruption compliance.
9.5. No Debarment. Consultant hereby represents and warrants that:
9.5.1. Consultant has not been debarred under Section 306(a) or Section 306(b) of the Federal Food, Drug and Cosmetic Act, as it may be amended from time to time, or any other local, state or federal law applicable to the pharmaceutical industry;
Fractyl Health Consulting Agreement with Jay Caplan
Page 6 of 12
9.5.2. Consultant has not been excluded from participation in any federal healthcare program under Section 1128 of the Social Security Act, as it may be amended from time to time, or any other local, state or federal healthcare fraud and abuse laws or false claims acts or applicable regulations;
9.5.3. Consultant has not been convicted of a criminal offense that falls within the scope of mandatory exclusion from participation in any Federal healthcare program under 42 U.S.C. §§ 1320a-7(a) or 1320a-7(b)(1)-(3); and
9.5.4. Consultant shall promptly notify Company if Consultant, during the Term of this Agreement, is excluded, debarred, suspended or otherwise ruled ineligible, or if any action is taken that could reasonably lead to such status. Company may terminate this Agreement immediately upon such notice or upon becoming aware of such action.
9.6. Disclosure of Payments. Consultant acknowledges that Company may be required under Section 1128G of the Social Security Act, its regulations, and other comparable federal, state, or foreign laws to disclose certain payments and other transfers of value provided to health care professionals and institutions, including payments and reimbursements made in connection with the Services. Consultant agrees that such information may be disclosed without additional notice or consent and may become publicly available. Consultant will provide Company or its designee with any information necessary for the Company to comply with the foregoing.
9.7. Securities Laws and MNPI. Consultant further acknowledges that Company is a publicly traded company subject to applicable federal securities laws, Securities and Exchange Commission (“SEC”) regulations, and applicable stock exchange rules. In the course of performing the Services under this Agreement, Consultant may receive, access or otherwise become aware of MNPI. Consultant shall not use or disclose MNPI except as expressly permitted under this Agreement or applicable law and shall not purchase, sell, or recommend the purchase or sale of any Company securities while in possession of MNPI or otherwise engage in conduct that would violate applicable insider trading or other securities laws. Consultant shall comply with all applicable securities laws, SEC regulations, and applicable stock exchange rules governing its conduct and shall reasonably cooperate with Company, upon Company’s reasonable request, by providing information and assistance necessary to enable Company to comply with its applicable public company disclosure and other legal obligations.
Fractyl Health Consulting Agreement with Jay Caplan
Page 7 of 12
Fractyl Health, Inc.
3 Van de Graaff Drive, Suite 200
Burlington, MA 01803
Attention: Sarah Toomey, General Counsel
If notice is given to the Consultant, it shall be sent to the address on file with the Company
Fractyl Health Consulting Agreement with Jay Caplan
Page 8 of 12
[Signature Page Follows]
Fractyl Health Consulting Agreement with Jay Caplan
Page 9 of 12
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date.
FRACTYL HEALTH, INC.
By: /s/Lara Smith Weber
Name: Lara Smith Weber
Title: Chief Financial Officer
CONSULTANT
By: /s/Jay Caplan
Name: Jay Caplan
Fractyl Health Consulting Agreement with Jay Caplan
Page 10 of 12
Exhibit A
Scope of Work
Fee Schedule
Consultant shall be compensated at a rate of $250 per hour, with a monthly cap of forty (40) hours, payable forty-five (45) days following receipt by the Company of a report identifying the work performed by Consultant and the time devoted to such work, provided that the services identified have been performed satisfactorily.
Services
The Consultant shall provide advice, historical context, and support to the Company’s executive team regarding program transitions, medical affairs publication support, product engineering advice, research and development, technical and operational matters, IP advice, and other ad hoc basis as requested by the Chief Executive Officer (the “Services”):
The Services described above shall be conducted with and in coordination with Harith Rajagopalan, CEO, or his designee.
Fractyl Health Consulting Agreement with Jay Caplan
Page 11 of 12